SA
Go ProLog In
PCVX
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
11 analysts·Moderate coverage
75
Score
11 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
11100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$77.00
+47.0%
Consensus
$83.00
+58.4%
Bull
$89.00
+69.9%
12-Month Target Range11 analysts
$77.00$83.00$89.00
Current $52.39Consensus
Current Price
$52.39
Upside to Consensus
$30.61

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+248.58%
EPS—
FY2028
Rev+103.31%
EPS—
FY2029
Rev+740.93%
EPS—

Earnings Surprises

Recent Analyst Actions

Feb 25, 2026BTIG
Vaxcyte (PCVX) PT Raised to $89 at BTIG
Target:$89.00
+41.2%from $63.04
Nov 19, 2025Leerink Partners
Vaxcyte (PCVX) PT Raised to $77 at Leerink Partners
Target:$77.00
+55.5%from $49.53
Nov 6, 2024Jefferies
Vaxcyte (PCVX) PT Raised to $146 at Jefferies
Target:$146.00
+36.8%from $106.73
Nov 6, 2024Leerink Partners
Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX)
Target:$135.00
+26.5%from $106.73
Sep 10, 2024Mizuho Securities
Vaxcyte price target raised to $163 from $113 at Mizuho
Target:$163.00
+41.4%from $115.28
Sep 4, 2024Bank of America Securities
Vaxcyte price target raised to $140 from $101 at BofA
Target:$140.00
+27.1%from $110.15
Sep 3, 2024Leerink Partners
Vaxcyte price target raised to $153 at Leerink after VAX-31 'home run'
Target:$153.00
+36.6%from $112.04
Sep 3, 2024BTIG
Vaxcyte (PCVX) PT Raised to $160 at BTIG
Target:$160.00
+45.3%from $110.15
Sep 3, 2024Jefferies
Vaxcyte (PCVX) PT Raised to $129 at Jefferies
Target:$129.00
+16.1%from $111.13
Sep 3, 2024Mizuho Securities
Mizuho Reiterates Outperform Rating on Vaxcyte (PCVX)
Target:$113.00
+1.7%from $111.08
Aug 7, 2024BTIG
BTIG Reiterates Buy Rating on Vaxcyte (PCVX)
Target:$98.00
+39.0%from $70.52
Jan 3, 2023Needham
Needham Maintains Buy on Vaxcyte, Raises Price Target to $58
Target:$58.00
+21.0%from $47.95
Dec 16, 2022Leerink Partners
SVB Leerink Initiates Coverage On Vaxcyte with Outperform Rating, Announces Price Target of $60
Target:$60.00
+31.9%from $45.48
Dec 15, 2022Guggenheim
Guggenheim Initiates Coverage On Vaxcyte with Buy Rating, Announces Price Target of $66
Target:$66.00
+44.4%from $45.72
Nov 17, 2022BTIG
BTIG Initiates Coverage On Vaxcyte with Buy Rating, Announces Price Target of $69
Target:$69.00
+59.2%from $43.35

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance